MCL1 and neoplasm: Although si-NPs targeting Mcl-1 remain to be tested in vivo, Mcl-1-specific inhibition in cell culture-based models dramatically reduced Mcl-1 expression in both LTED and parental breast cancer cells (Figs. 4a and  5b), increasing tumor cell killing in cells that have developed resistance to current standard of care therapies.